A5013528612- Electroconvulsive Therapy Studies
- Treatment of Major Depression
- Anesthesia and Sedative Agents
- Bipolar Disorder and Treatment
- Schizophrenia research and treatment
- Transcranial Magnetic Stimulation Studies
- Amino Acid Enzymes and Metabolism
- Perfectionism, Procrastination, Anxiety Studies
- Metabolism and Genetic Disorders
- Takotsubo Cardiomyopathy and Associated Phenomena
- Pharmacology and Obesity Treatment
- Retinal and Optic Conditions
- Family Caregiving in Mental Illness
- Forensic Anthropology and Bioarchaeology Studies
- Cardiac, Anesthesia and Surgical Outcomes
- Neurological and metabolic disorders
- Cyclopropane Reaction Mechanisms
- Healthcare professionals’ stress and burnout
- Child Nutrition and Feeding Issues
- Neurological disorders and treatments
- Glycogen Storage Diseases and Myoclonus
- Genetics and Neurodevelopmental Disorders
- Obsessive-Compulsive Spectrum Disorders
- Infectious Encephalopathies and Encephalitis
- Cardiovascular Syncope and Autonomic Disorders
Hospital General de Granollers
2007-2025
Short and Associates (United States)
2025
Universitat de València
2024
Universitat Internacional de Catalunya
2021-2022
Hospital Mare de Déu de la Mercè
2017
Universitat Autònoma de Barcelona
2005
The stigma surrounding electroconvulsive therapy (ECT) among healthcare professionals can lead to a lack of training, limit accessibility treatment, and introduce variability in its application. aim this study was explore the attitudes knowledge regarding ECT within professionals. A total 215 from Vallès Oriental region (Barcelona) completed translated version Questionnaire on Attitudes Knowledge (QuAKE). relationship between attitude scores analyzed relation several demographic variables...
Abstract Inherited monoamine neurotransmitter disorders (iMNDs) are rare with clinical manifestations ranging from mild infantile hypotonia, movement to early severe encephalopathy. Neuroimaging has been reported as non‐specific. We systematically analyzed brain MRIs in order characterize and better understand neuroimaging changes re‐evaluate the diagnostic role of MRI iMNDs. 81 70 patients (0.1‐52.9 years, 39 tetrahydrobiopterin deficiencies, 31 primary metabolism) were retrospectively...
Clozapine is a major atypical antipsychotic drug used in treatment-resistant schizophrenia (Patel and Allin. Ther Adv Psychopharmacol 2011;1:25-29). It interferes with dopamine binding to D1, D2, D3, D5 receptors but has high affinity D4. also an anticholinergic effect antagonizes α-adrenergic, histaminergic, serotoninergic (Oerther Ahlenius. J Pharmacol Exp 2000;292:731-736). proved effective treating positive negative symptoms patients refractory schizophrenia, thus accounting for its...
The determination of anesthetic depth has been used to assess the optimal moment for applying electrical stimuli in electroconvulsive therapy (ECT), as some anesthetics can reduce its effectiveness. In this study, seizure quality was assessed using measurement with patient state index (PSI).
Introduction The practice of electroconvulsive therapy (ECT) exhibits variability across various domains, both between regions, and centers within the same region. ECT Working Group Catalan Society Psychiatry conducted a comprehensive survey in Catalonia, Spain, to assess current status those variables essential clinical ECT. Materials Methods comprised 50 items, including question types such as multiple-choice, numerical response, open-ended questions. It was administered 20 public...
Department of Psychiatry Benito Menni CASM Hospital de Granollers Barcelona, Spain [email protected] The authors have no conflicts interest or financial disclosures to report.
A 71-year-old woman with history of major recurrent depressive syndrome responsive to clomipramine (last episode at 50-year-old) the following medical records: ischaemic stroke progressive cognitive impairment extent requiring wheelchair. Current Depressive symptoms, suicidal thoughts, anxiety, tremor and low food intake in last month (due choke phobia) up 10 kg weight loss. Diagnosis Major resistant treatment Parkinson syndrome. Treatment Lorazepam mg/day levodopa 150/carbidopa 37.5 mg/day,...